ArticleJournal of neurology, neurosurgery, and psychiatry2023
Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression.
Article in Journal of neurology, neurosurgery, and psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Smoking and disability outcomes in multiple sclerosis: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Targeting progressive multiple sclerosis: Toward mechanism-informed precision medicine.Journal of internal medicine · 2026Review
- Interaction between smoking andMultiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Migration status, country of origin and long-term outcomes in multiple sclerosis: a Swedish nationwide study.Journal of neurology, neurosurgery, and psychiatry · 2026Article
- Longitudinal Changes in Neutrophil-to-Lymphocyte and Monocyte-to-Lymphocyte Ratios During Multiple Sclerosis Relapse.Journal of clinical medicine · 2026Article
- Temporal Trends in the Incidence and Prevalence of Multiple Sclerosis in Sweden, 2001-2021.Neuroepidemiology · 2026Article
- Trajectories of processing speed in multiple sclerosis across disease-modifying therapies.Journal of neurology · 2026Article
- Preventive strategies in neuroimmunology.Neurological research and practice · 2026Review
- IL-27-964 A/G polymorphism promoter polymorphism, serum IL-27, and vitamin D in multiple sclerosis: evidence from an egyptian case-control study.Molecular biology reports · 2026Article
- Dental-amalgam exposure and the risk and progression of multiple sclerosis.International journal of epidemiology · 2026Article
- Article
- Long-term disability after initiation of platform versus high-efficacy disease-modifying therapy in relapsing-onset multiple sclerosis.Journal of neurology · 2026Article
- The lung-brain axis: elucidating the mechanisms of pulmonary-driven neurological disorders.Journal of neuroinflammation · 2026Review
- Multiple sclerosis and the limits of classical autoimmune theory.Frontiers in immunology · 2026Review
- Impact of tobacco and alcohol consumption on disease progression and MRI in people with multiple sclerosis: results of the prospective cohort study NationMS.Therapeutic advances in neurological disorders · 2026Article
- Smoking accelerates immunosenescence in multiple sclerosis.Frontiers in immunology · 2026Review
- Investigating the treatment of vascular risk with simvastatin in secondary progressive multiple sclerosis: analysis from the MS-STAT2 randomized controlled trial.Brain communications · 2026Article
- Determinants and prognostic value of onset symptoms in multiple sclerosis.Journal of neurology · 2025Article
- Timing and Predictive Value of Clinical Conditions Preceding Multiple Sclerosis in the UK Biobank.Annals of clinical and translational neurology · 2025Article
- Lifestyle factors associated with benign multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to study the influence of smoking habits, exposure to passive smoking and snuff use on disease progression, cognitive performance and quality of life in patients with multiple sclerosis (MS).
methodPatients from two population-based case-control studies were categorised based on tobacco exposure at diagnosis and were followed up to 15 years post diagnosis through the Swedish MS registry (n=9089) regarding changes in Expanded Disability Status Scale (EDSS), Multiple Sclerosis Impact Scale 29 and Symbol Digit Modalities Test. We used linear mixed models to analyse long-term changes, and Cox regression models with 95% CI using 24-week confirmed disability worsening, reaching EDSS 3 and EDSS 4, respectively, physical and psychological worsening and cognitive disability worsening as end points. The influence of smoking cessation post diagnosis was also investigated.
resultsCompared with non-smokers, current smokers had a faster EDSS progression (β
conclusionsOur findings indicate that both smoking and passive smoking have a negative influence on MS and that smoking cessation post diagnosis may be an important secondary preventive measure. Snuff use was associated with slower disease progression, suggesting that nicotine replacement therapy could be an attractive way to increase the chance of quitting smoking among patients with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.